# Study Evaluating a Gene Therapy for IPEX Syndrome Through the Expression of FOXP3 on Deficient T Cells to Produce Tregs-like.

> **NCT07697118** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 5 (estimated)

## Conditions studied

- The Immune Dysregulation Polyendocrinopathy Enteropathy X-linked Syndrome is a Primary Immunodeficiency Caused by Pathogenic Variants in Forkhead Box Protein 3

## Interventions

- **GENETIC:** FOXP3-T4 drug product
- **DRUG:** ILT-101

## Key facts

- **NCT ID:** NCT07697118
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2028-09
- **Final completion:** 2029-01
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2026-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07697118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07697118, "Study Evaluating a Gene Therapy for IPEX Syndrome Through the Expression of FOXP3 on Deficient T Cells to Produce Tregs-like.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07697118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*